These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
403 related articles for article (PubMed ID: 18824604)
1. Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa. Schurek KN; Marr AK; Taylor PK; Wiegand I; Semenec L; Khaira BK; Hancock RE Antimicrob Agents Chemother; 2008 Dec; 52(12):4213-9. PubMed ID: 18824604 [TBL] [Abstract][Full Text] [Related]
2. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Islam S; Oh H; Jalal S; Karpati F; Ciofu O; Høiby N; Wretlind B Clin Microbiol Infect; 2009 Jan; 15(1):60-6. PubMed ID: 19154484 [TBL] [Abstract][Full Text] [Related]
3. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. MacLeod DL; Nelson LE; Shawar RM; Lin BB; Lockwood LG; Dirk JE; Miller GH; Burns JL; Garber RL J Infect Dis; 2000 Mar; 181(3):1180-4. PubMed ID: 10720551 [TBL] [Abstract][Full Text] [Related]
4. Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres). Dubois V; Arpin C; Dupart V; Scavelli A; Coulange L; André C; Fischer I; Grobost F; Brochet JP; Lagrange I; Dutilh B; Jullin J; Noury P; Larribet G; Quentin C J Antimicrob Chemother; 2008 Aug; 62(2):316-23. PubMed ID: 18467306 [TBL] [Abstract][Full Text] [Related]
5. Role of the MexXY multidrug efflux pump in moderate aminoglycoside resistance in Pseudomonas aeruginosa isolates from Pseudomonas mastitis. Chuanchuen R; Wannaprasat W; Ajariyakhajorn K; Schweizer HP Microbiol Immunol; 2008 Aug; 52(8):392-8. PubMed ID: 18667038 [TBL] [Abstract][Full Text] [Related]
6. Transcriptional and Mutational Profiling of an Aminoglycoside-Resistant Pseudomonas aeruginosa Small-Colony Variant. Schniederjans M; Koska M; Häussler S Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874369 [No Abstract] [Full Text] [Related]
7. Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides. El'Garch F; Jeannot K; Hocquet D; Llanes-Barakat C; Plésiat P Antimicrob Agents Chemother; 2007 Mar; 51(3):1016-21. PubMed ID: 17194835 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260 [TBL] [Abstract][Full Text] [Related]
10. Determinants of intrinsic aminoglycoside resistance in Pseudomonas aeruginosa. Krahn T; Gilmour C; Tilak J; Fraud S; Kerr N; Lau CH; Poole K Antimicrob Agents Chemother; 2012 Nov; 56(11):5591-602. PubMed ID: 22908149 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804 [TBL] [Abstract][Full Text] [Related]
12. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia. Treerat P; Widmer F; Middleton PG; Iredell J; George AM FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356 [TBL] [Abstract][Full Text] [Related]
13. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. Plasencia V; Borrell N; Maciá MD; Moya B; Pérez JL; Oliver A Antimicrob Agents Chemother; 2007 Jul; 51(7):2574-81. PubMed ID: 17470655 [TBL] [Abstract][Full Text] [Related]
14. Aminoglycoside antibiotics induce bacterial biofilm formation. Hoffman LR; D'Argenio DA; MacCoss MJ; Zhang Z; Jones RA; Miller SI Nature; 2005 Aug; 436(7054):1171-5. PubMed ID: 16121184 [TBL] [Abstract][Full Text] [Related]
16. In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin. Martha B; Croisier D; Durand D; Hocquet D; Plesiat P; Piroth L; Portier H; Chavanet P Clin Microbiol Infect; 2006 May; 12(5):426-32. PubMed ID: 16643518 [TBL] [Abstract][Full Text] [Related]
17. [Mechanisms of pandrug-resistance of Pseudomonas aeruginosa]. Shen JL; Zhu DM; Wang MG Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1859-62. PubMed ID: 19040025 [TBL] [Abstract][Full Text] [Related]
18. Functional characterization of MexXY and OpmG in aminoglycoside efflux in Pseudomonas aeruginosa. Chuanchuen R; Wannaprasat W; Schweizer HP Southeast Asian J Trop Med Public Health; 2008 Jan; 39(1):115-22. PubMed ID: 18567450 [TBL] [Abstract][Full Text] [Related]
19. High-level antibiotic resistance in Pseudomonas aeruginosa biofilm: the ndvB gene is involved in the production of highly glycerol-phosphorylated beta-(1->3)-glucans, which bind aminoglycosides. Sadovskaya I; Vinogradov E; Li J; Hachani A; Kowalska K; Filloux A Glycobiology; 2010 Jul; 20(7):895-904. PubMed ID: 20348539 [TBL] [Abstract][Full Text] [Related]
20. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa. Hocquet D; Muller A; Blanc K; Plésiat P; Talon D; Monnet DL; Bertrand X Antimicrob Agents Chemother; 2008 Mar; 52(3):1173-5. PubMed ID: 18180356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]